Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Orthocell Ltd ( (AU:OCC) ) has provided an update.
Orthocell Limited has bolstered its executive leadership team with the appointments of Jim Piper as Chief Financial Officer and Adam Wood as Chief Commercial Officer. These strategic hires are aimed at supporting the company’s global expansion and commercialization efforts, particularly in the United States, as it seeks to enhance market engagement and product sales. Piper and Wood bring extensive experience in finance and commercial operations, respectively, which is expected to drive Orthocell’s growth and establish Remplir™ as a leading solution in the nerve repair market.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company focused on developing and commercializing innovative medical products. The company specializes in regenerative medicine solutions, with a particular emphasis on its flagship nerve repair device, Remplir™, targeting a global nerve repair market valued at over US$3.5 billion.
Average Trading Volume: 1,300,670
Technical Sentiment Signal: Buy
Current Market Cap: A$304.2M
Learn more about OCC stock on TipRanks’ Stock Analysis page.